scholarly journals Can red cell distribution width be a new parameter for predicting higher CD34+ cell count in the harvest?

2018 ◽  
Vol 51 (1) ◽  
pp. 47-52
Author(s):  
Eren Gündüz ◽  
Tuba Bulduk ◽  
Hava Üsküdar Teke ◽  
Ahmet Musmul ◽  
Neslihan Andıç
Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4882-4882
Author(s):  
Joel David Bessman ◽  
Maria Montoya

Abstract After treatment with imatinib, the majority of patients with chronic myelogenous leukemia (CML) achieve hematologic remission. This includes normalization of blood counts (red cells, white cells, and platelets) normalization of the white cell differential, and disappearance of abnormal immature cells from the peripheral blood. However, abnormal erythropoiesis may be more subtle than abnormal red cell counts. We reviewed two other indices of erythropoiesis, the mean cell volume (MCV) and the red cell distribution width (RDW). We studied 15 patients with a diagnosis of CML confirmed by BCR-ABL, in whom the first-line therapy was imatinib. Treatment dosage varied from 400 – 800 mg/day. Pre-treatment, all patients had an elevated white cell count, 14 of 15 had a low hemoglobin, and 11 of 15 had an abnormal high platelet count. None had an abnormal MCV (mean, 91.3, range 82 – 97), and 13 of 15 had an abnormal RDW (mean 16.2, range 14.1 – 19.2). After treatment was started, all 15 achieved a normal white cell count, hemoglobin, and platelet count within 3 months. All continued to have a normal MCV, with no apparent change (mean 92.1, range 82 – 98). However, after treatment 14 of 15 developed a normal RDW (mean 13.7, range 12.0 – 15.2). The RDW progressively declined during the first 3 months after treatment and reached an asymptote at that time. We conclude that hematopoiesis normalizes qualitatively as well as quantitatively after successful imatinib therapy of CML. Future study will determine whether an isolated elevated RDW will predict relapse or briefer duration of remission.


2016 ◽  
Vol 115 (01) ◽  
pp. 126-134 ◽  
Author(s):  
Trygve S. Ellingsen ◽  
Tove Skjelbakken ◽  
Ellisiv B. Mathiesen ◽  
Inger Njølstad ◽  
Tom Wilsgaard ◽  
...  

SummaryRed cell distribution width (RDW), a measure of the variability in size of the circulating erythrocytes, is associated with cardiovascular morbidity and mortality. We aimed to investigate whether RDW was associated with incident stroke and case fatality in subjects recruited from the general population. Baseline characteristics were obtained from 25,992 subjects participating in the fourth survey of the Tromsø Study, conducted in 1994/95. Incident stroke was registered from inclusion until December 31, 2010. Cox regression models were used to calculate hazard ratios (HR) with 95 % confidence intervals (95 % CI) for stroke, adjusted for age, sex, body mass index, smoking, haemoglobin level, white blood cell count, thrombocyte count, hypertension, total cholesterol, triglycerides, self-reported diabetes, and red blood cell count. During a median follow-up of 15.8 years, 1152 participants experienced a first-ever stroke. A 1 % increment in RDW yielded a 13 % higher risk of stroke (multivariable HR: 1.13, 95 % CI: 1.07–1.20). Subjects with RDW in the highest quintile compared to the lowest had a 37 % higher risk of stroke in multivariable analysis (HR: 1.37, 95 % CI: 1.11–1.69). Subjects with RDW above the 95-percentile had 55 % higher risk of stroke compared to those in the lowest quintile (HR: 1.55, 95 % CI: 1.16–2.06). All risk estimates remained unchanged after exclusion of subjects with anaemia (n=1102). RDW was not associated with increased risk of death within one year or during the entire follow-up after an incident stroke. RDW is associated with incident stroke in a general population, independent of anaemia and traditional atherosclerotic risk factors.


Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 710
Author(s):  
Francesco Petrella ◽  
Monica Casiraghi ◽  
Davide Radice ◽  
Andrea Cara ◽  
Gabriele Maffeis ◽  
...  

Background: The ratio of hemoglobin to red cell distribution width (HRR) has been described as an effective prognostic factor in several types of cancer. The aim of this study was to investigate the prognostic role of preoperative HRR in resected-lung-adenocarcinoma patients. Methods: We enrolled 342 consecutive patients. Age, sex, surgical resection, adjuvant treatments, pathological stage, preoperative hemoglobin, red cell distribution width, and their ratio were recorded for each patient. Results: Mean age was 66 years (SD: 9.0). There were 163 females (47.1%); 169 patients (49.4%) had tumors at stage I, 71 (20.8%) at stage II, and 102 (29.8%) at stage III. In total, 318 patients (93.0%) underwent lobectomy, and 24 (7.0%) pneumonectomy. Disease-free survival multivariable analysis disclosed an increased hazard ratio (HR) of relapse for preoperative HRR lower than 1.01 (HR = 2.20, 95%CI: (1.30–3.72), p = 0.004), as well as for N1 single-node (HR = 2.55, 95%CI: (1.33–4.90), p = 0.005) and multiple-level lymph node involvement compared to N0 for both N1 (HR = 9.16, 95%CI:(3.65–23.0), p < 0.001) and N2 (HR = 10.5, 95%CI:(3.44–32.2, p < 0.001). Conclusion: Pre-operative HRR is an effective prognostic factor of disease-free survival in resected-lung-adenocarcinoma patients, together with the level of pathologic node involvement.


2021 ◽  
Vol 25 (5) ◽  
pp. 2505-2516
Author(s):  
Maria Aparecida Knychala ◽  
Mario da Silva Garrote‐Filho ◽  
Breno Batista da Silva ◽  
Samantha Neves de Oliveira ◽  
Sarah Yasminy Luz ◽  
...  

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Yousef Ahmed ◽  
Manal A. Mahmoud

An amendment to this paper has been published and can be accessed via the original article.


Sign in / Sign up

Export Citation Format

Share Document